[go: up one dir, main page]

MX2016012965A - Metodo para preparar amg 416. - Google Patents

Metodo para preparar amg 416.

Info

Publication number
MX2016012965A
MX2016012965A MX2016012965A MX2016012965A MX2016012965A MX 2016012965 A MX2016012965 A MX 2016012965A MX 2016012965 A MX2016012965 A MX 2016012965A MX 2016012965 A MX2016012965 A MX 2016012965A MX 2016012965 A MX2016012965 A MX 2016012965A
Authority
MX
Mexico
Prior art keywords
amg
prepare
shpt
mbd
ckd
Prior art date
Application number
MX2016012965A
Other languages
English (en)
Other versions
MX374205B (es
Inventor
Jones Sian
BEZEMER Jeroen
Chen Ying
Crockett Richard
CROSSLEY Kevin
Cui Sheng
Huang Liang
LOWER Asher
RANGANATHAN Krishnakumar
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54241346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016012965(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2016012965A publication Critical patent/MX2016012965A/es
Publication of MX374205B publication Critical patent/MX374205B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Glass Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporciona un método para preparar AMG 416, o una sal farmacéuticamente aceptable del mismo. El AMG 416 es un agonista de péptido selectivo de ocho aminoácidos, sintético, del receptor sensible al calcio. Está siendo desarrollado como un tratamiento intravenoso de hiperparatiroidismo secundario (SHPT) en pacientes con hemodiálisis con enfermedad renal crónica - trastorno mineral y óseo (CKD-MBD).
MX2016012965A 2014-04-03 2015-04-03 Metodo para preparar amg 416. MX374205B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974899P 2014-04-03 2014-04-03
PCT/US2015/024347 WO2015154031A1 (en) 2014-04-03 2015-04-03 Method for preparing amg 416

Publications (2)

Publication Number Publication Date
MX2016012965A true MX2016012965A (es) 2017-07-06
MX374205B MX374205B (es) 2025-03-05

Family

ID=54241346

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012965A MX374205B (es) 2014-04-03 2015-04-03 Metodo para preparar amg 416.

Country Status (27)

Country Link
US (3) US10407464B2 (es)
EP (3) EP3126373B1 (es)
JP (1) JP6710158B2 (es)
KR (1) KR102397271B1 (es)
CN (3) CN119899242A (es)
AU (1) AU2015240527B2 (es)
CA (1) CA2944194C (es)
CL (1) CL2016002513A1 (es)
CY (1) CY1123100T1 (es)
DK (1) DK3126373T3 (es)
EA (1) EA032597B1 (es)
ES (2) ES2786225T3 (es)
HR (1) HRP20200527T1 (es)
HU (1) HUE048489T2 (es)
IL (1) IL248059B2 (es)
LT (1) LT3126373T (es)
MA (2) MA52906A (es)
ME (1) ME03781B (es)
MX (1) MX374205B (es)
PL (1) PL3126373T3 (es)
PT (1) PT3126373T (es)
RS (1) RS60187B1 (es)
SG (1) SG11201608176VA (es)
SI (1) SI3126373T1 (es)
SM (1) SMT202000207T1 (es)
WO (1) WO2015154031A1 (es)
ZA (1) ZA201606844B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114376970A (zh) * 2013-06-28 2022-04-22 美国安进公司 Etelcalcetide (AMG 416)的稳定的液体制剂
MX374205B (es) 2014-04-03 2025-03-05 Amgen Inc Metodo para preparar amg 416.
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
WO2017162650A1 (en) 2016-03-23 2017-09-28 Bachem Holding Ag Method for preparing glucagon-like peptides
US10858390B2 (en) 2016-09-02 2020-12-08 Cem Corporation Use of excess carbodiimide for peptide synthesis at elevated temperatures
CN108101959B (zh) * 2016-11-24 2021-07-09 四川科伦药物研究院有限公司 一种制备高纯度多肽或其类似物的方法
CN106928171B (zh) * 2017-05-03 2019-08-13 成都郑源生化科技有限公司 Fmoc-Arg（Pbf）-OH的合成方法
TW201915009A (zh) * 2017-10-03 2019-04-16 中化合成生技股份有限公司 合成依特卡肽（Ｅｔｅｌｃａｌｃｅｔｉｄｅ）或其鹽類之方法
CN110498835B (zh) * 2018-05-17 2021-06-08 深圳翰宇药业股份有限公司 一种合成etelcalcetide的方法
CN109280078B (zh) * 2018-10-30 2019-06-25 成都诺和晟泰生物科技有限公司 一种制备维拉卡肽的方法
CN112062811B (zh) * 2019-06-10 2022-03-25 深圳翰宇药业股份有限公司 一种维拉卡肽的合成方法
WO2021038431A1 (en) * 2019-08-26 2021-03-04 Auro Peptides Ltd An improved process for the preparation of etelcalcetide hydrochloride
EP3875466A1 (en) * 2020-03-05 2021-09-08 Fresenius Kabi iPSUM S.r.l. Process for the synthesis of etelcalcetide
EP4144747A4 (en) 2020-06-03 2024-05-29 Chugai Seiyaku Kabushiki Kaisha EFFICIENT PEPTIDE CONDENSATION PROCESS FOR DIFFICULT SEQUENCES
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
TWI792442B (zh) 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法
CN114524860B (zh) * 2021-12-29 2025-01-24 深圳翰宇药业股份有限公司 一种Etelcalcetide的合成方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
EP0339695A3 (en) 1988-04-29 1990-05-30 Stichting Voor De Technische Wetenschappen A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates
SE9603465D0 (sv) 1996-09-23 1996-09-23 Astra Ab New compounds
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CA2703113A1 (en) 2007-10-27 2009-04-30 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
CN101250172B (zh) 2008-03-07 2012-05-02 上海瀚鸿化工科技有限公司 精氨酸双保护制备工艺
WO2010129520A1 (en) 2009-05-06 2010-11-11 Mallinckrodt Inc. Solid support for fmoc-solid phase synthesis of peptide acids
JP5270799B2 (ja) * 2009-07-29 2013-08-21 カイ・ファーマシューティカルズ・インコーポレイテッド 副甲状腺ホルモンを低減する治療剤
EP2560491A1 (en) * 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Peripheral opioid agonists and peripheral opioid antagonists
US20140024592A1 (en) * 2010-09-08 2014-01-23 Howard Florey Institute Of Experimental Physiology And Medicine Modified Relaxin Polypeptides
WO2013042129A1 (en) 2011-09-23 2013-03-28 Natco Pharma Limited Improved process for preparation of bivalirudin
CN114376970A (zh) 2013-06-28 2022-04-22 美国安进公司 Etelcalcetide (AMG 416)的稳定的液体制剂
MX374205B (es) 2014-04-03 2025-03-05 Amgen Inc Metodo para preparar amg 416.
CN105504012A (zh) * 2014-09-30 2016-04-20 深圳翰宇药业股份有限公司 一种多肽的制备方法
CN107434820A (zh) * 2017-08-07 2017-12-05 南京工业大学 一种维拉卡肽的合成方法

Also Published As

Publication number Publication date
US11377474B2 (en) 2022-07-05
RS60187B1 (sr) 2020-06-30
EP3126373B1 (en) 2020-03-04
SI3126373T1 (sl) 2020-06-30
BR112016022868A2 (pt) 2018-07-03
HRP20200527T1 (hr) 2020-06-26
JP2017511332A (ja) 2017-04-20
HUE048489T2 (hu) 2020-07-28
SMT202000207T1 (it) 2020-05-08
MA39628B1 (fr) 2020-05-29
US20230099078A1 (en) 2023-03-30
EA201692001A1 (ru) 2017-02-28
LT3126373T (lt) 2020-05-11
CN106795201A (zh) 2017-05-31
CA2944194A1 (en) 2015-10-08
AU2015240527A1 (en) 2016-10-20
EP3126373A1 (en) 2017-02-08
US20190352336A1 (en) 2019-11-21
JP6710158B2 (ja) 2020-06-17
KR102397271B1 (ko) 2022-05-16
EP3126373A4 (en) 2018-06-20
EP4219526A3 (en) 2023-08-30
CA2944194C (en) 2022-04-19
ES2943671T3 (es) 2023-06-15
CN119874825A (zh) 2025-04-25
IL248059B1 (en) 2023-06-01
EA032597B1 (ru) 2019-06-28
CY1123100T1 (el) 2021-10-29
US10407464B2 (en) 2019-09-10
EP3708576A1 (en) 2020-09-16
ME03781B (me) 2021-04-20
SG11201608176VA (en) 2016-10-28
ES2786225T3 (es) 2020-10-09
IL248059B2 (en) 2023-10-01
MA52906A (fr) 2021-04-21
CL2016002513A1 (es) 2018-03-23
DK3126373T3 (da) 2020-05-04
KR20170026326A (ko) 2017-03-08
PT3126373T (pt) 2020-04-24
EP4219526A2 (en) 2023-08-02
ZA201606844B (en) 2018-07-25
US20170190739A1 (en) 2017-07-06
CN119899242A (zh) 2025-04-29
AU2015240527B2 (en) 2019-09-26
IL248059A0 (en) 2016-11-30
WO2015154031A1 (en) 2015-10-08
PL3126373T3 (pl) 2020-07-27
MX374205B (es) 2025-03-05
EP3708576B1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
MX2016012965A (es) Metodo para preparar amg 416.
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CO2018000809A2 (es) Anticuerpos para cd40
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
EA201791093A1 (ru) Антитела к cd47, способы и применение
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
EA201791882A1 (ru) Агонисты 5ht для лечения нарушений
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX2017009694A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
CO2017005500A2 (es) Método para la producción de un sistema de administración farmacéutica
AR099707A1 (es) Composiciones y métodos para tratar trastornos renales
CL2017000050A1 (es) Terapia de combinación para el cáncer
CR20160002A (es) Formulación estable líquida de etelcalcetide (amg 461)
MX373268B (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
PL3277272T3 (pl) Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego
UY36455A (es) Antagonistas del receptor ep3 de prostaglandinas
EA201591513A1 (ru) Терапевтическое применение антител к vegfr1 (варианты)
CL2018000290A1 (es) Antagonistas del receptor de cgrp
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
BR112019001409A2 (pt) células renais bioativas para o tratamento de doença renal crônica
MX2017005884A (es) Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.

Legal Events

Date Code Title Description
FG Grant or registration